These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9741193)

  • 1. [Hypolipemic treatment in prevention of secondary ischemic heart disease].
    Nessler J
    Przegl Lek; 1998; 55(5):259-65. PubMed ID: 9741193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular risk factors and prevention in women: similarities and differences].
    Sclavo M
    Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of lipid metabolism disorders in the elderly].
    Mizera W; Grzeszczak W
    Wiad Lek; 1998; 51 Suppl 2():52-7. PubMed ID: 9686534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation and treatment of lipid disorders in women.
    Zelis R
    Curr Womens Health Rep; 2003 Apr; 3(2):97-103. PubMed ID: 12628078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
    Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lipids and acute coronary syndromes].
    Stejfa M
    Vnitr Lek; 2000 Sep; 46(9):520-5. PubMed ID: 11344644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Secondary prevention of patients with ischaemic heart disease--the reduction of LDL cholesterol level and the regression of atherosclerosis].
    Bárczi G; Merkely B
    Lege Artis Med; 2007 Oct; 17(10):675-9. PubMed ID: 19227597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperlipidemia in patients with ischemic heart disease].
    Murase T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():722-7. PubMed ID: 11347161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.